IBR120
IBR120 is a RAD51 inhibitor. IBR120 inhibits homologous recombination (HR) repair and attenuates RAD51-DNA interaction by binding to the hydrophobic pocket of the RAD51 core domain and disrupting RAD51 multimerization. IBR120 induces apoptotic cell death and inhibits the proliferation of a broad spectrum of cancer cell lines. IBR120 in combination with anticancer agents such as EGFR inhibitors and microtubule agents produces synergistic anti-proliferative effects. IBR120 can be used in research related to breast cancer, chronic myeloid leukemia, osteosarcoma, cervical cancer, and glioblastoma.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 1704699-99-9
- 화학식: C23H20N2O2S
- 분자량:388.48
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocol
- 순도&문서
- References
-
Help & FAQs
Biological Activity
제품 설명
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MCF-10A | IC50 |
>30 μM
|
Cytotoxicity against normal human mammary gland epithelial MCF10A cells assessed by XTT cell viability assay after four-day treatment.
Cytotoxicity against normal human mammary gland epithelial MCF10A cells assessed by XTT cell viability assay after four-day treatment.
|
25874343 |
| K562 | IC50 |
3.6 μM
|
Growth inhibition activity against K562 cells assessed by XTT cell viability assay after four-day treatment.
Growth inhibition activity against K562 cells assessed by XTT cell viability assay after four-day treatment.
|
25874343 |
| MCF7 | IC50 |
3.1 μM
|
Growth inhibition activity against MCF7 cells assessed by XTT cell viability assay after four-day treatment.
Growth inhibition activity against MCF7 cells assessed by XTT cell viability assay after four-day treatment.
|
25874343 |
| MDA-MB-231 | IC50 |
3.5 μM
|
Growth inhibition activity against MBA-MD-231 cells assessed by XTT cell viability assay after four-day treatment.
Growth inhibition activity against MBA-MD-231 cells assessed by XTT cell viability assay after four-day treatment.
|
25874343 |
| MDA-MB-361 | IC50 |
4.5 μM
|
Growth inhibition activity against MBA-MD-361 cells assessed by XTT cell viability assay after four-day treatment.
Growth inhibition activity against MBA-MD-361 cells assessed by XTT cell viability assay after four-day treatment.
|
25874343 |
| MDA-MB-468 | IC50 |
3.1 μM
|
Growth inhibition activity against human MBA-MD-468 cells assessed by XTT cell viability assay after four-day treatment.
Growth inhibition activity against human MBA-MD-468 cells assessed by XTT cell viability assay after four-day treatment.
|
25874343 |
| MDA-MB-435 | IC50 |
4.0 μM
|
Growth inhibition activity against human MBA-MD-435 cells assessed by XTT cell viability assay after four-day treatment.
Growth inhibition activity against human MBA-MD-435 cells assessed by XTT cell viability assay after four-day treatment.
|
25874343 |
| Hs-578T | IC50 |
4.9 μM
|
Growth inhibition activity against Hs578-T cells assessed by XTT cell viability assay after four-day treatment.
Growth inhibition activity against Hs578-T cells assessed by XTT cell viability assay after four-day treatment.
|
25874343 |
| T47D | IC50 |
6.3 μM
|
Growth inhibition activity against T47D cells assessed by XTT cell viability assay after four-day treatment.
Growth inhibition activity against T47D cells assessed by XTT cell viability assay after four-day treatment.
|
25874343 |
| U2OS | IC50 |
4.7 μM
|
Growth inhibition activity against U2OS cells assessed by XTT cell viability assay after four-day treatment.
Growth inhibition activity against U2OS cells assessed by XTT cell viability assay after four-day treatment.
|
25874343 |
| T98G | IC50 |
9.5 μM
|
Growth inhibition activity against T98G cells assessed by XTT cell viability assay after four-day treatment.
Growth inhibition activity against T98G cells assessed by XTT cell viability assay after four-day treatment.
|
25874343 |
| HeLa | IC50 |
3.6 μM
|
Growth inhibition activity against HeLa cells assessed by XTT cell viability assay after four-day treatment.
Growth inhibition activity against HeLa cells assessed by XTT cell viability assay after four-day treatment.
|
25874343 |
In Vitro
IBR120 (4 days) selectively inhibits the growth of multiple cancer cell lines (K562, MCF7, MDA-MB-231, MDA-MB-361, MDA-MB-435, MDA-MB-468, Hs578-T, T47D, U2OS, T98G, HeLa) with IC50 values of 3~5 μM, while exhibiting significantly lower toxicity to normal MCF10A cells, with IC50 > 30 μM[1].
IBR120 (10-20 µM; 24) inhibits homologous recombination repair in HeLa cells stably expressing DR-GFP in a dose-dependent manner[1].
IBR120 (4 days) significantly enhances the killing effect of various chemotherapeutic agents on cancer cells, such as Osimertinib (HY-15772), Afatinib (HY-10261), Lapatinib (HY-50898), Imatinib (HY-15463), Vemurafenib (HY-12057), Regorafenib (HY-10331), Enzalutamide (HY-70002), and Vincristine (HY-N0488A), reducing the IC50 of these anticancer agents by up to 90%[2].
IBR120 (24 h) reduced RAD51 protein levels by more than 80% in NSCLC cell lines[2].
IBR120 inhibits HR, SSA, and Alt-EJ, but not NHEJ, in U2OS cells[3].
IBR120 inhibits RAD51 foci formation in TNBC cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1704699-99-9
-
분자량 388.48
-
화학식 C23H20N2O2S
-
SMILES
O=S(CC1=CC=CC=C1)(N2[C@@H](C3=CNC4=CC=CC=C34)C5=CC=CC=C5C2)=O
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
IBR120 Related Classifications
HY-176549A Related Classifications
Powered by Bioz